To investigate the proportional changes of CD4+CD25+ regulatory T cells in peripheral blood after lymphocyte therapy in unexplained recurrent spontaneous abortion (URSA) patients.
Some of these include immunological testing and treatment, allogenic lymphocyte therapy, intratubal transfer of zygotes and embryos, blastocyst transfer, sequential embryo transfer, assisted hatching, co-cultures, and preimplantation genetic screening for aneuploidy.
The risk increases with the intensity of induction or rescue immunosuppression, and particularly following monoclonal or polyclonal anti-lymphocyte therapy.
Clinically applied modalities of cancer immunotherapy include the adoptive transfer of cellular immune effectors by means of allogeneic stem cell transplantation and donor lymphocyte therapy, monoclonal antibodies with direct and indirect cytotoxic mechanisms, and active immunotherapy with cellular and acellular vaccines.
Because early B-cell precursors do not express CD20, the bone marrow is able to repopulate B lymphocytes after therapy.
In two studies (consisting altogether of 14 patients), the clinical and serologic responses to B lymphocyte depletion therapy in IgG4-RD patients who remained refractory to steroids and DMARDs were assessed.
B lymphocyte depletion therapy utilising rituximab has been shown to be an effective treatment for active refractory lupus.
We previously demonstrated prolonged, profound CD4+ T-lymphopenia in rheumatoid arthritis (RA) patients following lymphocyte-depleting therapy.
Cyclophosphamide, together with high-dose glucocorticoids, was introduced empirically for induction treatment of AAV over 40 years ago, as a lymphocyte-depleting therapy following its use in lymphoproliferative diseases.
Donor lymphocyte infusion therapy, and particularly the adoptive transfer of adenovirus-specific T cells represents a promising approach for the treatment of immunocompromised patients [ 17, 18], but its efficacy is still under investigation.
